Incorporation of Machine Learning Tools to Predict Global Outcomes for Patients with Relapsed and Refractory Peripheral T and NK/T-Cell Lymphomas in the Contemporary Era
Leora Boussi(Beth Israel Deaconess Medical Center), Salvia Jain(Broad Institute), Carlos Chiattone(Hospital Samaritano de São Paulo), Mubarak Al‐Μansour(King Abdulaziz Medical City), Ijeoma Julie Eche(Dana-Farber Cancer Institute), Josie Ford(University of Connecticut), Martina Manni(University of Modena and Reggio Emilia), H. Miles Prince(Peter MacCallum Cancer Centre), Massimo Federico(University of Modena and Reggio Emilia), Francine M. Foss(Yale Cancer Center), Mwanasha H. Merrill(Dana-Farber Cancer Institute), Eliana Miranda(Santa Casa Hospital), Jackielyn Cuenca Alturas(King Abdulaziz Medical City), Min Ji Koh(Georgetown University), Estelle Verburgh(Groote Schuur Hospital), Carrie van der Weyden(Peter MacCallum Cancer Centre), Sang Eun Yoon(Sungkyunkwan University), Beatrice Casadei(Istituto di Ematologia di Bologna), Takeshi Okatani(Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital), María Elena Cabrera(Hospital del Salvador), Min Jung Koh(Georgetown University), Eric D. Jacobsen(Dana-Farber Cancer Institute), Girisha Panchoo(University of Cape Town), Luke Peng(Dana-Farber Brigham Cancer Center), Shambhavi Singh(Massachusetts General Hospital), Pier Luigi Zinzani(Istituto di Ematologia di Bologna), Enrica Marchi(Columbia University Irving Medical Center), Xinyi Han(Massachusetts Institute of Technology), Owen A. O’Connor(Virginia Cancer Institute), Won-Seog Kim(Samsung Medical Center), Noriaki Yoshida(Dana-Farber Cancer Institute)
Cited by 1
Related Papers
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
|The Lancet Oncology|2010|852
Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
|Journal of Clinical Oncology|2011|657